146 related articles for article (PubMed ID: 22053655)
1. Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
Ota T; Takeshima N; Takizawa K
Eur J Gynaecol Oncol; 2011; 32(5):471-5. PubMed ID: 22053655
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Arimoto T; Nakagawa S; Oda K; Kawana K; Yasugi T; Taketani Y
Med Oncol; 2012 Jun; 29(2):1253-4. PubMed ID: 21380784
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
Escobar PF; Markman M; Rose P; Zanotti K; Webster K; Belinson J
Gynecol Oncol; 2004 Jan; 92(1):192-6. PubMed ID: 14751157
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
Markman M; Zanotti K; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2003 Dec; 91(3):573-6. PubMed ID: 14675679
[TBL] [Abstract][Full Text] [Related]
8. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
9. ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Lee M; Kim SW; Nam EJ; Cho H; Kim JH; Kim YT; Kim S
Yonsei Med J; 2014 Nov; 55(6):1664-71. PubMed ID: 25323906
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Seliger G; Mueller LP; Kegel T; Kantelhardt EJ; Grothey A; Groe R; Strauss HG; Koelbl H; Thomssen C; Schmoll HJ
Int J Gynecol Cancer; 2009 Nov; 19(8):1446-53. PubMed ID: 20009905
[TBL] [Abstract][Full Text] [Related]
12. SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Clamp AR; Mäenpää J; Cruickshank D; Ledermann J; Wilkinson PM; Welch R; Chan S; Vasey P; Sorbe B; Hindley A; Jayson GC;
Br J Cancer; 2006 Jan; 94(1):55-61. PubMed ID: 16404360
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Clin Oncol; 2001 Apr; 19(7):1901-5. PubMed ID: 11283121
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Kelly MG; Mor G; Husband A; O'Malley DM; Baker L; Azodi M; Schwartz PE; Rutherford TJ
Int J Gynecol Cancer; 2011 May; 21(4):633-9. PubMed ID: 21412168
[TBL] [Abstract][Full Text] [Related]
15. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A
Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523
[TBL] [Abstract][Full Text] [Related]
16. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Pautier P; Joly F; Kerbrat P; Bougnoux P; Fumoleau P; Petit T; Rixe O; Ringeisen F; Carrasco AT; Lhommé C
Gynecol Oncol; 2010 Feb; 116(2):157-62. PubMed ID: 20109725
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
Polyzos A; Kosmas C; Toufexi H; Malamos N; Lagadas A; Kosmidis C; Ginopoulos P; Ziras N; Kandilis K; Georgoulias V
Anticancer Res; 2005; 25(5):3559-64. PubMed ID: 16101180
[TBL] [Abstract][Full Text] [Related]
19. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
20. Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin.
Ueda Y; Enomoto T; Matsuzaki S; Kobayashi E; Kimura T; Yoshino K; Fujita M; Tsutsui T; Kimura T
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1411-6. PubMed ID: 23515753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
